CVM - CEL-SCI Corp Short-Term Debt to Capital

The price action of CEL-SCI Corporation (CVM) with the 0.26 indicator demonstrates the development of an immune stimulation system, where the Multikine drug helps the body fight tumors prior to surgical intervention. The company is currently engaged in a complex struggle for regulatory approvals, carefully managing its funds until the start of sales. In the future, patent protection of the core technology will provide the business with high profitability, free cash flow, and pricing power.

This ratio determines the company's dependence on current liabilities by comparing the volume of short-term loans to equity to assess current liquidity and refinancing risks. Analyzing the chart of short-term liabilities as a share of equity allows an investor to evaluate the financial stability of CEL-SCI Corporation (CVM), whose strategy of long-term oncology research requires stable, long-term financing without excessive pressure from operational debts.